Chitosan sponges to locally deliver amikacin and vancomycin

A pilot in vitro evaluation

Scott P. Noel, Harry Courtney, Joel D. Bumgardner, Warren O. Haggard

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Background: Open orthopaedic wounds are ideal sites for infection. Preventing infection in these wounds is critical for reducing patient morbidity and mortality, controlling antimicrobial resistance and lowering the cost of treatment. Localized drug delivery has the potential to overcome the challenges associated with traditional systemic dosing. A degradable, biocompatible polymer sponge (chitosan) that can be loaded with clinician-selected antibiotics at the point of care would provide the patient and clinician with a desirable, adjunctive preventive modality. Questions/purposes: We asked (1) if an adaptable, porous chitosan matrix could absorb and elute antibiotics for 72 hours for potential use as an adjunctive therapy to débridement and lavage; and (2) if the sponges could elute levels of antibiotic that would inhibit growth of Staphylococcus aureus and Pseudomonas aeruginosa? Methods: We fabricated a degradable chitosan sponge that can be loaded with antibiotics during a 60-second hydration in drug-containing solution. In vitro evaluation determined amikacin and vancomycin release from chitosan sponges at six time points. Activity tests were used to assess the release of inhibitory levels of amikacin and vancomycin. Results: Amikacin concentration was 881.5 μg/mL after 1 hour with a gradual decline to 13.9 μg/mL after 72 hours. Vancomycin concentration was 1007.4 μg/mL after 1 hour with a decrease to 48.1 μg/mL after 72 hours. Zone of inhibition tests were used to verify inhibitory levels of drug release from chitosan sponges. A turbidity assay testing activity of released amikacin and vancomycin indicated inhibitory levels of elution from the chitosan sponge. Clinical Relevance: Chitosan sponges may provide a potential local drug delivery device for preventing musculoskeletal infections.

Original languageEnglish (US)
Pages (from-to)2074-2080
Number of pages7
JournalClinical Orthopaedics and Related Research
Volume468
Issue number8
DOIs
StatePublished - Jan 1 2010

Fingerprint

Amikacin
Chitosan
Porifera
Vancomycin
Anti-Bacterial Agents
Point-of-Care Systems
Pharmaceutical Preparations
Therapeutic Irrigation
Wound Infection
Infection
In Vitro Techniques
Health Care Costs
Pseudomonas aeruginosa
Orthopedics
Staphylococcus aureus
Polymers
Morbidity
Equipment and Supplies
Mortality
Wounds and Injuries

All Science Journal Classification (ASJC) codes

  • Surgery
  • Orthopedics and Sports Medicine

Cite this

Chitosan sponges to locally deliver amikacin and vancomycin : A pilot in vitro evaluation. / Noel, Scott P.; Courtney, Harry; Bumgardner, Joel D.; Haggard, Warren O.

In: Clinical Orthopaedics and Related Research, Vol. 468, No. 8, 01.01.2010, p. 2074-2080.

Research output: Contribution to journalArticle

Noel, Scott P. ; Courtney, Harry ; Bumgardner, Joel D. ; Haggard, Warren O. / Chitosan sponges to locally deliver amikacin and vancomycin : A pilot in vitro evaluation. In: Clinical Orthopaedics and Related Research. 2010 ; Vol. 468, No. 8. pp. 2074-2080.
@article{92176caa007349509bd74a32aab4f6fe,
title = "Chitosan sponges to locally deliver amikacin and vancomycin: A pilot in vitro evaluation",
abstract = "Background: Open orthopaedic wounds are ideal sites for infection. Preventing infection in these wounds is critical for reducing patient morbidity and mortality, controlling antimicrobial resistance and lowering the cost of treatment. Localized drug delivery has the potential to overcome the challenges associated with traditional systemic dosing. A degradable, biocompatible polymer sponge (chitosan) that can be loaded with clinician-selected antibiotics at the point of care would provide the patient and clinician with a desirable, adjunctive preventive modality. Questions/purposes: We asked (1) if an adaptable, porous chitosan matrix could absorb and elute antibiotics for 72 hours for potential use as an adjunctive therapy to d{\'e}bridement and lavage; and (2) if the sponges could elute levels of antibiotic that would inhibit growth of Staphylococcus aureus and Pseudomonas aeruginosa? Methods: We fabricated a degradable chitosan sponge that can be loaded with antibiotics during a 60-second hydration in drug-containing solution. In vitro evaluation determined amikacin and vancomycin release from chitosan sponges at six time points. Activity tests were used to assess the release of inhibitory levels of amikacin and vancomycin. Results: Amikacin concentration was 881.5 μg/mL after 1 hour with a gradual decline to 13.9 μg/mL after 72 hours. Vancomycin concentration was 1007.4 μg/mL after 1 hour with a decrease to 48.1 μg/mL after 72 hours. Zone of inhibition tests were used to verify inhibitory levels of drug release from chitosan sponges. A turbidity assay testing activity of released amikacin and vancomycin indicated inhibitory levels of elution from the chitosan sponge. Clinical Relevance: Chitosan sponges may provide a potential local drug delivery device for preventing musculoskeletal infections.",
author = "Noel, {Scott P.} and Harry Courtney and Bumgardner, {Joel D.} and Haggard, {Warren O.}",
year = "2010",
month = "1",
day = "1",
doi = "10.1007/s11999-010-1324-6",
language = "English (US)",
volume = "468",
pages = "2074--2080",
journal = "Clinical Orthopaedics and Related Research",
issn = "0009-921X",
publisher = "Springer New York",
number = "8",

}

TY - JOUR

T1 - Chitosan sponges to locally deliver amikacin and vancomycin

T2 - A pilot in vitro evaluation

AU - Noel, Scott P.

AU - Courtney, Harry

AU - Bumgardner, Joel D.

AU - Haggard, Warren O.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Background: Open orthopaedic wounds are ideal sites for infection. Preventing infection in these wounds is critical for reducing patient morbidity and mortality, controlling antimicrobial resistance and lowering the cost of treatment. Localized drug delivery has the potential to overcome the challenges associated with traditional systemic dosing. A degradable, biocompatible polymer sponge (chitosan) that can be loaded with clinician-selected antibiotics at the point of care would provide the patient and clinician with a desirable, adjunctive preventive modality. Questions/purposes: We asked (1) if an adaptable, porous chitosan matrix could absorb and elute antibiotics for 72 hours for potential use as an adjunctive therapy to débridement and lavage; and (2) if the sponges could elute levels of antibiotic that would inhibit growth of Staphylococcus aureus and Pseudomonas aeruginosa? Methods: We fabricated a degradable chitosan sponge that can be loaded with antibiotics during a 60-second hydration in drug-containing solution. In vitro evaluation determined amikacin and vancomycin release from chitosan sponges at six time points. Activity tests were used to assess the release of inhibitory levels of amikacin and vancomycin. Results: Amikacin concentration was 881.5 μg/mL after 1 hour with a gradual decline to 13.9 μg/mL after 72 hours. Vancomycin concentration was 1007.4 μg/mL after 1 hour with a decrease to 48.1 μg/mL after 72 hours. Zone of inhibition tests were used to verify inhibitory levels of drug release from chitosan sponges. A turbidity assay testing activity of released amikacin and vancomycin indicated inhibitory levels of elution from the chitosan sponge. Clinical Relevance: Chitosan sponges may provide a potential local drug delivery device for preventing musculoskeletal infections.

AB - Background: Open orthopaedic wounds are ideal sites for infection. Preventing infection in these wounds is critical for reducing patient morbidity and mortality, controlling antimicrobial resistance and lowering the cost of treatment. Localized drug delivery has the potential to overcome the challenges associated with traditional systemic dosing. A degradable, biocompatible polymer sponge (chitosan) that can be loaded with clinician-selected antibiotics at the point of care would provide the patient and clinician with a desirable, adjunctive preventive modality. Questions/purposes: We asked (1) if an adaptable, porous chitosan matrix could absorb and elute antibiotics for 72 hours for potential use as an adjunctive therapy to débridement and lavage; and (2) if the sponges could elute levels of antibiotic that would inhibit growth of Staphylococcus aureus and Pseudomonas aeruginosa? Methods: We fabricated a degradable chitosan sponge that can be loaded with antibiotics during a 60-second hydration in drug-containing solution. In vitro evaluation determined amikacin and vancomycin release from chitosan sponges at six time points. Activity tests were used to assess the release of inhibitory levels of amikacin and vancomycin. Results: Amikacin concentration was 881.5 μg/mL after 1 hour with a gradual decline to 13.9 μg/mL after 72 hours. Vancomycin concentration was 1007.4 μg/mL after 1 hour with a decrease to 48.1 μg/mL after 72 hours. Zone of inhibition tests were used to verify inhibitory levels of drug release from chitosan sponges. A turbidity assay testing activity of released amikacin and vancomycin indicated inhibitory levels of elution from the chitosan sponge. Clinical Relevance: Chitosan sponges may provide a potential local drug delivery device for preventing musculoskeletal infections.

UR - http://www.scopus.com/inward/record.url?scp=77954702937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954702937&partnerID=8YFLogxK

U2 - 10.1007/s11999-010-1324-6

DO - 10.1007/s11999-010-1324-6

M3 - Article

VL - 468

SP - 2074

EP - 2080

JO - Clinical Orthopaedics and Related Research

JF - Clinical Orthopaedics and Related Research

SN - 0009-921X

IS - 8

ER -